Announcing Leadership Transitions in Pharmacology and Physiology
November 16, 2026
Olimpia Meucci, MD, PhD, professor and chair of the Department of Pharmacology and Physiology, is transitioning to the position of senior vice president for research, innovation, and strategic partnerships, a University-wide role in which Dr. Meucci will help shape the future of Drexel's research enterprise, strengthen interdisciplinary collaborations and strategic partnerships, and foster a culture of research excellence and innovation.
This appointment recognizes Dr. Meucci’s outstanding accomplishments as a scientist, educator and academic leader, as well as her longstanding commitment to Drexel University. Since becoming chair in 2016, she has led a remarkable transformation of the Department of Pharmacology and Physiology, including a fourfold increase in research expenditures and $80 million in research awards. She also expanded graduate education programs and established new research initiatives and partnerships, including TRaCES, a translational research platform connecting basic scientists and clinicians.
An internationally recognized physician-scientist, Dr. Meucci has made pioneering contributions to neuroimmunology and cancer research. Her achievements include a prestigious 10-year NIH-NIDA MERIT Award, election as a fellow of the National Academy of Inventors, and numerous honors recognizing her scientific contributions, mentorship and leadership, including the College of Medicine's Elias Abrutyn Mentorship Award and Daniel V. Schidlow Transformational Leadership Award. She is a 2012 graduate of the Executive Leadership in Academic Medicine (ELAM) program. Dr. Meucci has been a dedicated advocate for faculty and trainee development and cross-disciplinary collaboration. We are deeply grateful for her contributions to the College.
Seena Ajit, PhD, professor of pharmacology and physiology, has been appointed interim chair of the department, effective November 16, 2026.
Dr. Ajit joined the College of Medicine as an assistant professor in November 2009 and was promoted to professor of pharmacology and physiology in 2023. Before joining the College of Medicine, she worked in research and development at Wyeth Research (now part of Pfizer), where she focused on target identification and led a drug discovery program in pain therapeutics.
Dr. Ajit leads an NIH-funded research program focused on understanding the molecular and neuroimmune mechanisms underlying pain, identifying novel biomarkers and developing non-opioid therapeutic approaches. Her research explores the roles of epigenetic regulation, noncoding RNAs, and extracellular vesicle-mediated communication in pain and inflammation. In addition to her NIH funding, her work has been supported by the Rita Allen Foundation and the PhRMA Foundation, among others, and has resulted in numerous peer-reviewed publications.
Dr. Ajit is actively involved in graduate education and mentorship, contributing lectures to the biomedical sciences core curriculum, Pharmacology and Physiology graduate courses, and Responsible Conduct of Research, while also leading a graduate-level grant writing course and serving on several graduate student thesis committees. She has mentored eight PhD graduates, along with master's students, postdoctoral fellows and undergraduate researchers. She is also a multiple principal investigator of the recently funded NIH T32 training program, “Advanced Training in Translational Research and Clinical Target Discovery.” Her commitment to mentorship has been recognized through several awards, including the College of Medicine's 2026 Award for Excellence in Basic Science Mentoring and graduate student mentoring awards in 2016 and 2024.
Dr. Ajit has contributed extensively to institutional and professional service, including graduate education, faculty development and academic governance. She previously served as a standing member of the NIH Neurobiology of Pain and Itch Study Section and continues to participate in national and international grant review activities. She currently serves as vice president of the Mid-Atlantic Pharmacology Society, a regional chapter of the American Society for Pharmacology and Experimental Therapeutics, and she will assume the presidency in January 2027. She is a 2026 graduate of the ELAM program.